cGMP FDA

Blog & News

FDA Proposes Exclusion of GLP-1s from the 503B Bulks List: Implications for Outsourcing Facilities

FDA Proposes Exclusion of GLP-1s from the 503B Bulks List: Implications for Outsourcing Facilities

The U.S. Food and Drug Administration (FDA) continues to refine the regulatory framework governing compounded medications, introducing significant implications...

Read more Regulatory Updates
Optimizing Metabolic Protocols: The Synergistic Role of Levocarnitine, L-Arginine, and Active B12

Optimizing Metabolic Protocols: The Synergistic Role of Levocarnitine, L-Arginine, and Active B12

Medical weight management continues to evolve as practitioners seek safe, effective adjunctive therapies to support patients beyond standard diet and exercise r...

Read more Clinical & Technical Insights
Overcoming Formulation Challenges in Sterile Peptide Injectables and Complex Therapeutics

Overcoming Formulation Challenges in Sterile Peptide Injectables and Complex Therapeutics

Peptide therapeutics and complex coenzymes represent one of the fastest-growing sectors in modern medicine. By bridging the gap between small-molecule drugs and...

Read more Case Studies & White Papers